Company / Current Assets
Gain Therapeutics, Inc. Current Assets History
FY2021-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$11.6M
FY2024
5-year range
$11.6M / $37.7M
FY2021-FY2024
Trend
-34.7%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Assets has declined for 3 consecutive years, from $38M in FY2021 to $12M in FY2024.
Based on SEC 10-K filings.
$12M in FY2024 with a 3-year CAGR of -32.5%.
Declined from $21M to $12M over the past 2 years.
Current Assets over time
Growth rates
- 3-Year CAGR
- -32.5%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Gain Therapeutics, Inc.'s current assets has declined for 3 consecutive years.
- 3-year CAGR of -32.5%, indicating a declining trend.
- In FY2024, current assets decreased 34.7% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -16.87 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $11.6M | -34.7% |
| FY2023 | $17.8M | -15.7% |
| FY2022 | $21.1M | -44.1% |
| FY2021 | $37.7M | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026